Does sildenafil affect uroflowmetry values in men with lower urinary tract symptoms suggestive of benign prostatic enlargement?

Urologia Internationalis

Volumn 80, Issue 2, 2008, Pages 181-185

  Güler, Cem ^a   Tüzel, Emre ^a,b   Doǧantekin, Engin ^a   Kiziltepe, Güneş ^a  

^a AFYON KOCATEPE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b NONE   (Turkey)

Author keywords

Benign prostate enlargement; Phosphodiesterase inhibitors; Sildenafil; Uroflowmetry

Indexed keywords

SILDENAFIL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; HUMAN; LOWER URINARY TRACT SYMPTOM; MALE; MEDICAL PARAMETERS; MICTURITION; PILOT STUDY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; SYMPTOM; URINE FLOW RATE; URINE VOLUME; UROFLOWMETRY;

AGED; HUMANS; MALE; MIDDLE AGED; PHOSPHODIESTERASE INHIBITORS; PILOT PROJECTS; PIPERAZINES; PROSTATIC HYPERPLASIA; PROSTATISM; PURINES; SULFONES; URODYNAMICS;

EID: 41149173029     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000112611     Document Type: Article

References (20)

1. Madersbacher S, Alivizatos G, Nordling J, Sanz CR, Emberton M, de la Rosette JJMCH: EAU 2004 Guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH Guidelines). Eur Urol 2004;46:547-554.
2. Lin CS, Xin ZC, Lin G, Lue TF: Phosphodiesterases as therapeutic targets. Urology 2003;61:685-691.
3. Jeremy JY, Ballard SA, Naylor AM, Miller MAW, Angelini GD: Effects of sildenafil, a type 5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum in vitro. Br J Urol 1997;79:958-963.
4. Mamas MA, Reynard JM, Brading AF: Nitric oxide and the lower urinary tract: current concepts, future prospects. Urology 2003;61:1079-1085.
5. Reitz A, Müntener M, Haferkamp A, Hohenfellner M, Schurch B: Targeting bladder outlet obstruction from benign prostatic enlargement via the nitric oxide/cGMP pathway. BJU Int 2006;96:250-253.
6. Kamm KE, Stull JT: Regulation of smooth muscle contractile elements by second messengers. Annu Rev Physiol 1989;51:299-313.
7. Ückert S, Küthe A, Jonas U, Stief CG: Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J Urol 2001;166:2484-2490.
8. Ückert S, Oelke M, Stief CG, Andersson KE, Jonas U, Hedlund P: Immunohistochemical distribution of cAMP and cGMP phosphodiesterase isoenzymes in the human prostate. Eur Urol 2006;49:740-745.
9. Sairam K, Kulinskaya E, McNicholas TA, Boustead GB, Hanbury DC: Sildenafil influences lower urinary tract symptoms. BJU Int 2002;90:836-839.
10. Gonzales SR, Ogiste J, Weill TAE: Combination of an α1-blocker alfuzosin and a PDE5 inhibitor sildenafil citrate, is superior to monotherapy in treating lower urinary tract symptoms and sexual dysfunction. Eur Urol 2006;5(suppl 2):A699.
11. McVary KT, Camps J, Henry GD, Conner SD, Tseng LL, van den Ende G: Sildenafil improves erectile function and urinary symptoms in men with erectile dysfunction and concomitant lower urinary tract symptoms. J Urol 2006;175:A1637.
12. McVary KT, Roehrborn C, Kaminetsky J, Auerbach S, Wachs B, Young J, Esler A, Sides G, Denes B: The efficacy and safety of tadalafil administered once a day for lower urinary tract symptoms in men with benign prostatic hyperplasia. Eur Urol 2006;5(suppl 2):A696.
13. Porst H: Phosphodiesterase type 5 inhibitors: a critical comparative analysis. EAU Update Ser 2004;2:56-63.
14. van Verooij GEP, Boon TA: Size for the diagnosis of obstructive benign prostatic hyperplasia: a urodynamic analysis. J Urol 1996;155:2014-2018.
15. Golomb J, Lindner A, Siegel Y, Korczak D: Variability and circadian changes in home uroflowmetry in patients with benign prostatic hyperplasia compared to normal cohorts. J Urol 1992;147:1044-1047.
16. Reynard JM, Peters TJ, Lim C, Abrams P: The value of multiple free-flow studies in men with lower urinary tract symptoms. Br J Urol 1996;77:813-816.
17. Tong YC: The effect of psychological motivation on volumes voided during uroflowmetry in healthy aged male volunteers. Neurourol Urodyn 2006;25:8-12.
18. Chancellor MB, Blaivas JG, Kaplan SA, Axelrod S: Bladder outlet obstruction versus impaired detrusor contractility: the role of uroflow. J Urol 1991;145:810-812.
19. Reynard JM, Yang O, Donovan JL, Peters TJ, Schafer W, de la Rosette JJMCH, Dabhoiwala NF, Osawa D, Tong LLA, Abrams P: The ICS 'BPH' study: uroflowmetry, lower urinary tract symptoms and bladder outlet obstruction. Br J Urol 1998;82:619-623.
20. McVary KT: Lower urinary tract symptoms and sexual dysfunction: epidemiology and pathophysiology. BJU Int 2006;97(suppl 2):23-28.